In addition, analysis of molecular subtypes of breast cancer demonstrated a ∼40% relapse-free survival rate in node-negative, HER-2-positive patients who had not received any systemic therapy at all, with a median follow-up time of 9 years (Parker et al, 2009). Here, ERBB2 is linked to breast cancer.